IL-6–GP130 signaling protects human hepatocytes against lipid droplet accumulation in humanized liver models

Author:

Carbonaro Marisa1ORCID,Wang Kehui1,Huang Hui1,Frleta Davor1,Patel Aditi1ORCID,Pennington Alexander2,Desclaux Mathieu1,Moller-Tank Sven1ORCID,Grindley Justin1,Altarejos Judith1,Zhong Jun1,Polites Greg1,Poueymirou William1ORCID,Jaspers Stephen1,Kyratsous Christos1ORCID,Zambrowicz Brian1ORCID,Murphy Andrew1ORCID,Lin John C.1,Macdonald Lynn E.1ORCID,Daly Christopher1ORCID,Sleeman Mark1ORCID,Thurston Gavin1ORCID,Li Zhe1ORCID

Affiliation:

1. Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.

2. Pyxant Labs Inc., Salt Lake City, UT, USA.

Abstract

Liver steatosis is an increasing health issue with few therapeutic options, partly because of a paucity of experimental models. In humanized liver rodent models, abnormal lipid accumulation in transplanted human hepatocytes occurs spontaneously. Here, we demonstrate that this abnormality is associated with compromised interleukin-6 (IL-6)–glycoprotein 130 (GP130) signaling in human hepatocytes because of incompatibility between host rodent IL-6 and human IL-6 receptor (IL-6R) on donor hepatocytes. Restoration of hepatic IL-6–GP130 signaling, through ectopic expression of rodent IL-6R, constitutive activation of GP130 in human hepatocytes, or humanization of an Il6 allele in recipient mice, substantially reduced hepatosteatosis. Notably, providing human Kupffer cells via hematopoietic stem cell engraftment in humanized liver mice also corrected the abnormality. Our observations suggest an important role of IL-6–GP130 pathway in regulating lipid accumulation in hepatocytes and not only provide a method to improve humanized liver models but also suggest therapeutic potential for manipulating GP130 signaling in human liver steatosis.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3